Page 497 - Economia Azul - versão: inglês

materials and reagents that ensure the research that results in scientific publica- 5. Startups and Entrepreneurship
maintenance of a favorable environment tions and patents in Health Sciences has
for obtaining of the final biological prod- been decreasing in the last 10 years, in Brazil is a highly entrepreneurial country. by 41.9% between 2011 and 2014, show-
uct. Thus, considering the research time some areas such as Antibiotics/Biofilm and According to the Global Entrepreneurship ing that there is still room for biotechnology
required to obtain a biological medicine Anticancer there is still a large proportion Monitor Brazil, in 2016, for every 100 inhab- growth in the country. Furthermore, in the
that has been proven to be safe and ef- of scientific publications when compared itants, 36 were entrepreneurs, a rate higher 2018 edition of BioBr magazine, prominent
fective, it is expected that the Brazilian to the patents (Figure 5). Thus, this may than many other Latin American countries companies and organizations shared their
patent system will be dynamic and fast be one of the greatest national challenges and even some “developed” countries. This views on the biotechnology landscape in Bra-
in relation to the area of Biotechnology. for greater development and use of knowl- is reflected in the biotechnology sector, as zil and examples of their innovation activities.

Also, although the proportion between edge for the benefit of society in Brazil. there are many startups being created with Today’s entrepreneurship is increasingly relat-
a focus on projects in this area. ed to technological innovation, and biotech-
According to a mapping by the Brazilian nology is nothing more than innovation.
80000 Startup Association (ABStartups), there are According to studies by CEBRAP, de-
more than 4.2 million startups in Brazil, but veloped in partnership with BrBiotec and
70000
it is still difficult to estimate how many are APEX do Brasil, in 2011 Brazil had 237
working with biotechnology. To alleviate
biotechnology companies, 63% of which
Publications (2010-2022) 50000 and Apex-Brasil are working on mapping 78% of these companies depend on public
60000
this lack of data, Biominas Brasil, Abiquifi
were created in the last decade. However,
startups in Brazil that work with pharma-
funding to perform their functions. The most
40000
prominent area of activity is human health
ceutical ingredients, chemical and biologi-

30000
cal compounds, medical equipment, digital
research (about 40%), followed by animal
20000
health, human and animal pharmaceuti-
ronment and bioenergy together cover 25%
cals, animal nutrition and biotechnology health (14%). The areas of agriculture, envi-
10000
in general. It will also map the country’s of Brazilian biotechnology companies. Of all
0 main innovation clusters in these areas; the these entities, 80% are micro and small com-
Antiparasitic/ Pesticides
Antifungal/Pesticides
Antibiotics/Biofilm Anticancer Antiviral Neuroprotective Analgesic Antiihypertensive type of solutions being researched; and the panies that suffer from a lack of investment,
products already in the prototype phase.
unavailability of inputs, excessive bureaucra-
cy, and inexperience to complete the devel-
A survey conducted by Biominas (2017)
revealed the general profile of Brazilian bio-
technology companies. Most (about 60%) opment of their products.
Normally in the creation of companies
Publications Patents
are small, with up to 10 employees, and (Startups for example), although there are re-
young, under 10 years old. Almost 70% of sources available for the initial research phase,
Source: Own Elaboration (2022)
the companies have already carried out some there is usually a lack of product testing and
type of international cooperation and all re- the separation of incubators. The incubators
Figure 5. Publications and patents re- ywords anywhere in the text “biotech- spondents showed interest in carrying out fu- are normally maintained with a contribu-
gistered with Google Academic and nology”, “marine” and switching betwe- ture cooperation activities. Large companies tion of federal resources from the Financier
Google Patents, respectively, between en “anti-parasitic”, “antifungal”, “an- are also seeking innovation through biotech- of Studies and Projects (Finep - Financiado-
2010 and 2022. The search criteria were: tihypertensive”, “anti-inflammatory”,
articles or patents of any nature and “antiviral”, “neuroprotective”, “analge- nology projects. According to the Brazil Inno- ra de Estudos e Projetos), and the incubated
language, except revisions, with all ke- sic”, “antibiotic” and “anticancer”. vation Survey (PINTEC), the number of inno- companies depend on these resources both
vative companies using biotechnology grew to develop their products and to invest in

494 BLUE ECONOMY Development of Marine Biotechnology 495
494 BLUE ECONOMY